FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OIVID APPROVAL									
OMB Number:	3235-0287								
Estimated average but									
Louinaleu average bu	iiucii								

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

						` '										
1. Name and Address of Reporting Person* STAHL PAMELA J			<u> </u>	2. Issuer Name <b>and</b> Ticker or Trading Symbol INVIVO THERAPEUTICS HOLDINGS							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner					
					CORP. [ NVIV ]							Officer (below)	(give title		Other (s below)	·
(Last) (First) (Middle) C/O INVIVO THERAPEUTICS HOLDINGS CORP.				3. Date of Earliest Transaction (Month/Day/Year) 09/14/2016							Chief Commercial Officer					
		QUARE, SUITE			3/14/2	2010										
(Ott)				4.	If Ame	endment, [	Date o	of Original File	ed (Month/Da	ıy/Year)	6. Ir Line	idividual or J	oint/Group	Filing	(Check App	licable
(Street) CAMBR	IDGE N	ΛA	02139										•	•	rting Person	
									Form filed by More than One Reporting Person				ing			
(City)	(5	State)	(Zip)													
		Та	ble I - Non-De	erivati	ve Se	ecurities	s Ac	quired, D	isposed (	of, or Be	neficiall	y Owned				
Date			ransaction e onth/Day/		2A. Deemed Execution Date, if any (Month/Day/Yea		Code (Instr.			Beneficia Owned Fe	s Form ally (D) o following (I) (In		n: Direct I or Indirect I nstr. 4)	7. Nature of Indirect Beneficial Ownership		
							Code V	Amount	(A) o (D)	r Price	Reported Transacti (Instr. 3 a	on(s)			(Instr. 4)	
			Table II - Der (e.g					uired, Dis s, options				Owned				
Derivative Conversion Date Execusive Or Exercise (Month/Day/Year) if any		3A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)			
Stock Option (right to buy)	\$6.47	09/14/2016		A		188,200		(1)	09/14/2026	Common Stock	188,200	\$0	188,20	00	D	

## Explanation of Responses:

1. This option vests as to 25% of the shares on the first anniversary of the date of grant, with the remaining shares vesting in 36 equal monthly installments thereafter.

<u>/s/ Steven McAllister, as</u> attorney-in-fact <u>09/16/2016</u>

\*\* Signature of Reporting Person Dat

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.